The DOI matches its Crossref record; 146 of the 147 references it cites were found in a registry or an index.
Aβ Oligomers – a decade of discovery
Open accessAbstract
Converging lines of evidence suggest that progressive accumulation of the amyloid β‐protein (Aβ) plays a central role in the genesis of Alzheimer’s disease, but it was long assumed that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic Aβ peptides, cell culture models, β‐amyloid precursor protein transgenic mice and human brain to suggest that pre‐fibrillar, diffusible assemblies of Aβ are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the preformed Aβ42 fibrils, no significant cell toxicity was observed in either the absence or presence of Cu2+ (Figure 9, lanes 1 and 2), supporting the previously reported diminished toxicity of Aβ42 fibrils.5,7,54−56”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“This is confirmed by the decreased cell survival of 44±8% in presence of soluble Aβ42 oligomers (Figure 11, lane 2), supporting the increased neurotoxicity of Aβ42 oligomers versus Aβ42 fibrils.16,19”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 4×
“…performance in a hippocampaldependent contextual fear conditioning assay, decreased spine density in the dentate gyrus, and impairment of long-term potentiation (LTP) at ages long before the first apparent detection of Ab dodecamer (Dineley et al. 2002; Jacobsen et al. 2006; Lesne et al. 2006).”
BackgroundInfluentialRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Self-citationTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 3×
“The initial cleavage leading to amyloid b-protein (Ab) production is mediated by the aspartyl protease, b-secretase (also called b-amyloid cleaving enzyme-1, BACE-1), and occurs immediately N-terminal to the Ab domain, simultaneously generating APPsb and the membranetethered C-terminal fragment, C99 (Vassar et al. 199…”
Background
Research works printed but not linked: 2
- Selkoe D. J., 2003, Annu. Rev. Pharmacol. Toxicol., 545
- Shankar G. M., 2007, Natural oligomers of the Alzheimer amyloid beta‐protein induce hippocampal synapse loss but can be neutralized by antibodies and small molecules, J. Neurosci.
Cited by
Sorted by citations
Items 501–600 of 1,010
Cimini, A., Gentile, R., D’Angelo, B., Benedetti, E., Cristiano, L., Avantaggiati, M. L., Giordano, A., Ferri, C., & Desideri, G. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24548 · Cited by 80
Reifert, J. R., Hartung-Cranston, D., & Feinstein, S. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.234674 · Cited by 83
Fossati, S., Ghiso, J. A., & Rostagno, A. A. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.55 · Cited by 79
Zimbone, S., Monaco, I., Gianì, F., Pandini, G., Copani, A. G., Giuffrida, M. L., & Rizzarelli, E. (2018) · Aging Cell · doi:10.1111/acel.12684 · Cited by 79
APP transgenic mice: their use and limitations
Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79
Nanoscale structure of amyloid-β plaques in Alzheimer’s disease
Querol‐Vilaseca, M., Colom‐Cadena, M., Pegueroles, J., Núñez‐Llaves, R., Luque-Cabecerans, J., Muñoz, L., Andilla, J., Belbin, O., Spires‐Jones, T. L., Gelpí, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41443-3 · Cited by 81
Potential therapeutic agents against Alzheimer’s disease from natural sources
Park, S. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1010-y · Cited by 79
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Kuo, D. S., Labelle‐Dumais, C., Mao, M., Jeanne, M., Kauffman, W. B., Allen, J., Favor, J., & Gould, D. B. (2014) · Europe PMC (PubMed Central) · doi:10.1093/hmg/ddt560 · Cited by 3
miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease
Mushtaq, G., H. Greig, N., Anwar, F., A. Zamzami, M., Choudhry, H., M. Shaik, M., A. Tamargo, I., & A. Kamal, M. (2016) · Medicinal Chemistry · doi:10.2174/1573406411666151030112140 · Cited by 78
Akhter, R., Sanphui, P., Das, H., Saha, P., & Biswas, S. C. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13128 · Cited by 78
Identification and biology of α‐secretase
Vingtdeux, V., & Marambaud, P. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07477.x · Cited by 81
Eisele, Y. S., & Duyckaerts, C. J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1516-y · Cited by 82
Sun, Y., Qian, Z., & Wei, G. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp01014h · Cited by 77
Krishtal, J., Bragina, O., Metsla, K., Palumaa, P., & Tõugu, V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186636 · Cited by 76
Fruhwürth, S., Zetterberg, H., & Paludan, S. R. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578342 · Cited by 77
Ancelin, M., de Roquefeuil, G., Scali, J., Bonnel, F., Adam, J. J., Cheminal, J.-C., Cristol, J., Dupuy, A., Carrière, I., & Ritchie, K. A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100807 · Cited by 77
Amyloid β-Protein Assembly: The Effect of Molecular Tweezers CLR01 and CLR03
Zheng, X., Liu, D., Klärner, F., Schrader, T. H., Bitan, G., & Bowers, M. T. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b00692 · Cited by 79
Poling, A. D., Morgan-Paisley, K., Panos, J., Kim, E., O‘Hare, E., Cleary, J. P., Lesné, S., Ashe, K. H., Porritt, M., & Baker, L. E. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.001 · Cited by 77
Liu, T., & Bitan, G. (2012) · ChemMedChem · doi:10.1002/cmdc.201100585 · Cited by 77
Seed-induced acceleration of amyloid-β mediated neurotoxicity in vivo
Sowade, R. F., & Jahn, T. R. (2017) · Nature Communications · doi:10.1038/s41467-017-00579-4 · Cited by 78
Brain organoids: a next step for humanized Alzheimer’s disease models?
Gerakis, Y., & Hetz, C. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0343-7 · Cited by 64
Autoimmune and inflammatory mechanisms of CNS damage
Kapadia, M., & Šakić, B. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.008 · Cited by 75
Lista, S., Garaci, F., Ewers, M., Teipel, S. J., Zetterberg, H., Blennow, K., & Hampel, H. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.506 · Cited by 78
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis
Lavatelli, F., Imperiini, E., Orrù, S., Rognoni, P., Sarnataro, D., Palladini, G., Malpasso, G., Soriano, M. E., Fonzo, A. D., Valentini, V., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-272179 · Cited by 76
Hampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 82
Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
Prins, N. D., & Scheltens, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt220 · Cited by 79
Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
Wirths, O., & Zampar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218144 · Cited by 75
Amyloid Aggregation under the Lens of Liquid–Liquid Phase Separation
Xing, Y., Nandakumar, A., Käkinen, A., Sun, Y., Davis, T. P., Ke, P. C., & Ding, F. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02567 · Cited by 75
Therapeutic Potential of Phytoconstituents in Management of Alzheimer’s Disease
Singh, S. P., Nand, S., Maurya, A., Mishra, G., Awasthi, R., Shakya, A., Chellappan, D. K., Dua, K., Vamanu, E., Chaudhary, S. K., et al. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5578574 · Cited by 77
The Role of Aβ-Induced Calcium Dysregulation in the Pathogenesis of Alzheimer's Disease
Small, D. H., Gasperini, R., Vincent, A. J., Hung, A. C., & Foa, L. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0951 · Cited by 77
Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease
Hellström‐Lindahl, E., Viitanen, M. H., & Marutle, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.03.007 · Cited by 78
Chojnacki, J. E., Liu, K., Yan, X., Toldo, S. A., Selden, T. M., Estrada, M., Rodríguez-Franco, M. I., Halquist, M. S., Ye, D., & Zhang, S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500081s · Cited by 76
α-Synuclein Misfolding: Single Molecule AFM Force Spectroscopy Study
Yu, J., Málková, Š., & Lyubchenko, Y. L. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.006 · Cited by 74
Drago, D., Cavaliere, A., Mascetra, N., Ciavardelli, D., Ilio, C. D., Zatta, P. F., & Sensi, S. L. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0761 · Cited by 74
Bandara, N., Sharma, A. K., Krieger, S., Schultz, J. W., Han, B. H., Rogers, B. E., & Mirica, L. M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05937 · Cited by 82
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 78
Current perspectives on pharmacotherapy of Alzheimer's disease
Chopra, K., Misra, S., & Kuhad, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.520702 · Cited by 75
Cerebral amyloidosis: amyloid subunits, mutants and phenotypes
Rostagno, A. A., Holton, J. L., Lashley, T., Révész, T., & Ghiso, J. A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0182-4 · Cited by 80
Viayna, E., Sabaté, R., & Muñoz‐Torrero, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990139 · Cited by 77
High Stability and Cooperative Unfolding of α-Synuclein Oligomers
Pasławski, W., Andreasen, M., Nielsen, S. B., Lorenzen, N., Thomsen, K., Kaspersen, J. D., Pedersen, J. S., & Otzen, D. E. (2014) · Biochemistry · doi:10.1021/bi5007833 · Cited by 73
Jokar, S., Khazaei, S., Behnammanesh, H., Shamloo, A., Erfani, M., Beiki, D., & Bavi, O. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00606-2 · Cited by 76
Potential mechanisms and implications for the formation of tau oligomeric strains
Gerson, J. E., Mudher, A. K., & Kayed, R. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1226251 · Cited by 78
Díaz, A., Limón, I. D., Chávez, R., Zenteno, E., & Guevara, J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111979 · Cited by 73
Emanuel, J. E., López, O. L., Houck, P. R., Becker, J. T., Weamer, E. A., DeMichele‐Sweet, M. A. A., Kuller, L. H., & Sweet, R. A. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181e446c8 · Cited by 73
Granzotto, A., & Zatta, P. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021565 · Cited by 74
Detergent-like Interaction of Congo Red with the Amyloid β Peptide
Lendel, C., Bolognesi, B., Wahlström, A., Dobson, C. M., & Gräslund, A. (2010) · Biochemistry · doi:10.1021/bi902005t · Cited by 75
Calkins, M. J., Mańczak, M., & Reddy, P. (2012) · Pharmaceuticals · doi:10.3390/ph5101103 · Cited by 71
Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation
Merlo, S., & Sortino, M. A. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.02.005 · Cited by 77
Vitalis, A., & Caflisch, A. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.08.003 · Cited by 73
Balleza‐Tapia, H., Crux, S., Andrade‐Talavera, Y., Dolz-Gaitón, P., Papadia, D., Chen, G., Johansson, J., & Fisahn, A. (2018) · eLife · doi:10.7554/elife.37703 · Cited by 72
Bulati, M., Buffa, S., Martorana, A., Gervasi, F., Camarda, C., Azzarello, D. M., Monastero, R., Caruso, C., & Colonna-Romano, G. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142412 · Cited by 72
Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer’s disease
Bordji, K., Becerril-Ortega, J., & Buisson, A. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.029 · Cited by 75
Ghiso, J. A., Fossati, S., & Rostagno, A. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140027 · Cited by 73
Prion-like seeding and nucleation of intracellular amyloid-β
Olsson, T. T., Klementieva, O. L., & Gouras, G. K. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.015 · Cited by 74
Cerebral Serotonin 4 Receptors and Amyloid-β in Early Alzheimer's Disease
Madsen, K., Neumann, W., Holst, K. K., Marner, L., Haahr, M. E., Lehel, S., Knudsen, G. M., & Hasselbalch, S. G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110056 · Cited by 74
Takeda, S., Hashimoto, T., Roe, A. D., Hori, Y., Spires‐Jones, T. L., & Hyman, B. T. (2013) · The FASEB Journal · doi:10.1096/fj.13-229666 · Cited by 74
Gulisano, W., Melone, M., Puma, D. D. L., Tropea, M. R., Palmeri, A., Arancio, O., Grassi, C., Conti, F., & Puzzo, D. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.025 · Cited by 72
Sotolongo, K., Ghiso, J. A., & Rostagno, A. A. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0578-9 · Cited by 74
Early Stages for Parkinson’s Development: α-Synuclein Misfolding and Aggregation
Yu, J., & Lyubchenko, Y. L. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9115-5 · Cited by 71
Hroudová, J., Singh, N., Fišar, Z., & Ghosh, K. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.084 · Cited by 71
Jarosz-Griffiths, H., Whitehouse, I. J., Baybutt, H. N., Brown, D., Kellett, K. A. B., Jackson, C. D., Turner, A. J., Piccardo, P., Manson, J. C., & Hooper, N. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.278556 · Cited by 72
Cremades, N., & Dobson, C. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.009 · Cited by 72
Kostomoiri, M., Fragkouli, A., Sagnou, M., Skaltsounis, L., Pelecanou, M., Tsilibary, E. C., & Tzinia, A. (2012) · Cellular and molecular neurobiology · doi:10.1007/s10571-012-9880-9 · Cited by 68
CD 4 T cells in immunity and immunotherapy of A lzheimer's disease
Monsonego, A., Nemirovsky, A., & Harpaz, I. (2013) · Immunology · doi:10.1111/imm.12103 · Cited by 72
Srivastava, S., & Haigis, M. C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072526 · Cited by 70
Intrinsically Disordered Proteins: Where Computation Meets Experiment
Burger, V., Gurry, T., & Stultz, C. M. (2014) · Polymers · doi:10.3390/polym6102684 · Cited by 71
Jellinger, K. A., Janetzky, B., Attems, J., & Kienzl, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00313.x · Cited by 72
Sylla, T., Pouységu, L., Costa, G. D., Deffieux, D., Monti, J., & Quideau, S. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201411606 · Cited by 70
Amijee, H., Bate, C., Williams, A., Virdee, J. K., Jeggo, R., Spanswick, D. C., Scopes, D. I. C., Treherne, J. M., Mazzitelli, S., Chawner, R., et al. (2012) · Biochemistry · doi:10.1021/bi300415v · Cited by 72
Visual system manifestations of Alzheimer's disease
Kusne, Y. N., Wolf, A. B., Townley, K., Conway, M. D., & Peyman, G. A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13319 · Cited by 74
Xu, W., Fitzgerald, S. M., Nixon, R. A., Levy, E., & Wilson, D. A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.12.008 · Cited by 69
PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition
Kroker, K. S., Mathis, C., Marti, A., Cassel, J., Rosenbrock, H., & Dorner‐Ciossek, C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.023 · Cited by 69
Walsh, P. J., Vanderlee, G., Yau, J., Campeau, J. L., Sim, V. L., Yip, C. M., & Sharpe, S. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515866 · Cited by 69
Will anti-amyloid therapies work for Alzheimer's disease?
St George-Hyslop, P. H., & Morris, J. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61047-8 · Cited by 69
Armato, U., Chiarini, A., Chakravarthy, B., Chioffi, F., Pacchiana, R., Colarusso, E., Whitfield, J. F., & Dal Prà, I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.020 · Cited by 68
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
Inhibitors of protein aggregation and toxicity
Amijee, H., Madine, J., Middleton, D. A., & Doig, A. J. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370692 · Cited by 69
Cimini, A., Moreno, S., D’Amelio, M., Cristiano, L., D’Angelo, B., Falone, S., Benedetti, E., Carrara, P., Fanelli, F., Cecconi, F., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1199 · Cited by 70
Qu, W., Yuan, B., Li, R., Liu, Q., Zhang, X., Cui, R., Yang, W., & Li, B. (2020) · Cell Proliferation · doi:10.1111/cpr.12959 · Cited by 65
Lim, N. K.-H., Villemagne, V. L., Soon, C. P. W., Laughton, K. M., Rowe, C. C., McLean, C., Masters, C. L., Evin, G. M., & Li, Q. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101974 · Cited by 67
Glu-333 of Nicastrin Directly Participates in γ-Secretase Activity
Dries, D. R., Shah, S., Han, Y., Yu, C., Yu, S., Shearman, M. S., & Yu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.038737 · Cited by 67
Primate aging in the mammalian scheme: the puzzle of extreme variation in brain aging
Finch, C. E., & Austad, S. N. (2012) · AGE · doi:10.1007/s11357-011-9355-9 · Cited by 68
Zhou, W.-W., Lü, S., Su, Y., Xue, D., Yu, X., Wang, S., Zhang, H., Xu, P., Xie, X.-X., & Liu, R. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.013 · Cited by 68
The consequences of mitochondrial amyloid β-peptide in Alzheimer's disease
Muirhead, K. E. A., Borger, E., Aitken, L., Conway, S. J., & Gunn‐Moore, F. J. (2010) · Biochemical Journal · doi:10.1042/bj20091941 · Cited by 68
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 64
Belluti, F., Rampa, A., Gobbi, S., & Bisi, A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.772983 · Cited by 68
Alzheimer’s Disease Pathologic Cascades: Who Comes First, What Drives What
Swerdlow, R. H. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9272-9 · Cited by 69
Mura, E., Zappettini, S., Preda, S., Biundo, F., Lanni, C., Grilli, M., Cavallero, A., Olivero, G., Salamone, A., Govoni, S. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029661 · Cited by 65
Sinomenine inhibits microglial activation by Aβ and confers neuroprotection
Shukla, S. M., & Sharma, S. K. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-117 · Cited by 66
Wang, P., Su, C., Li, R., Wang, H., Ren, Y., Sun, H., Yang, J., Sun, J., Shi, J., Tian, J., et al. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23322 · Cited by 65
RetractedCutler, T., Sarkar, A., Moran, M. T., Steffensmeier, A. M., Puli, O. R., Mancini, G., Tare, M., Gogia, N., & Singh, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137691 · Cited by 68
Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis
Murray, P. S., Kirkwood, C. M., Gray, M. C., Fish, K. N., Ikonomović, M. D., Hamilton, R. L., Kofler, J., Klunk, W. E., López, O. L., & Sweet, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131166 · Cited by 67
Gonzalez‐Velasquez, F. J., Kotarek, J. A., & Moss, M. A. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05618.x · Cited by 67
CSF proteins and resting-state functional connectivity in Parkinson disease
Campbell, M. C., Koller, J. M., Snyder, A. Z., Buddhala, C., Kotzbauer, P. T., & Perlmutter, J. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001681 · Cited by 65
Béland, M., & Roucou, X. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07613.x · Cited by 65
A New Target for Amyloid Beta Toxicity Validated by Standard and High-Throughput Electrophysiology
Varghese, K., Molnár, P., Das, M., Bhargava, N., Lambert, S., Kindy, M. S., & Hickman, J. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008643 · Cited by 69
Nag, S., Chen, J., Irudayaraj, J., & Maiti, S. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.07.020 · Cited by 66
Neuroinflammation and Copper in Alzheimer’s Disease
Choo, X. Y., Alukaidey, L., White, A. R., & Grubman, A. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/145345 · Cited by 70
Kragh, C. L., Ubhi, K. K., Wyss‐Coray, T., & Masliah, E. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00545.x · Cited by 66
Metadata
- Authors
- Walsh, D. M., & Selkoe, D. J.
- Affiliations
- University College Dublin (IE)
- Brigham and Women's Hospital (US)
- Corresponding author
- Walsh, Dominic M.
- Selkoe, Dennis J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-04
- Volume
- 101
- Issue
- 5
- Pages
- 1172-1184
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1981458288
- Cited by
- 1,938
- References
- 147
- Citations by year
- 2026: 48 · 2025: 36 · 2024: 46 · 2023: 47 · 2022: 50 · 2021: 63 · 2020: 76 · 2019: 81 · 2018: 81 · 2017: 109 · 2016: 120 · 2015: 136 · 2014: 134 · 2013: 159 · 2012: 167
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Neurologic Diseases
- Wellcome Trust (067660)
- National Institutes of Health
- National Institute on Aging (AG-06173)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease, soluble amyloid-beta, synaptic loss, neuronal injury, amyloid fibrils, amyloid precursor protein, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Humans, Male, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Protein Structure, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
